HOME ABOUT CONTACT AVAILABLE ISSUES SUBSCRIBE MEDIA & ADS CONFERENCE CALENDAR
LATEST UPDATES » Volume 20, No. 6, June 2016 – Medical Devices & Healthcare Technology       » Seizing Opportunity in Asia-Pacific's Complex and Rapidly Changing Medical Device Market       » IoT in Healthcare       » High Performance Computing Cluster (HPC), Pearcey, a Result of CSIRO-Dell Partnership       » SONY Expanding Footprint in Medical Field       » Biosensors Announces Strategic Agreement with Cardinal Health       » Gene Decides How Young We Look      
INSIDE INDUSTRY
Cognoptix licenses AD detection technology
Cognoptix, which was known as Neuroptix until October, has exclusively licensed technology from the University of California, San Diego, which Cognoptix has developed into a non-invasive eye-scanning test for the early detection and diagnosis of Alzheimer's disease (AD). Cognoptix also revealed that it has established a Clinical Advisory Board, comprised of key opinion leaders from among the worldwide neuroscience community.

The Cognoptix Sapphire II system consists of a laser-based reading device and consumable ophthalmic ointment. The eye exam can be given by a general practitioner and only takes a few minutes to achieve a result. The Cognoptix drug/device combination is a novel, early-stage diagnostic for AD designed to allow treatment before significant neuronal loss and irreversible brain damage occurs. A ligand or contrast agent and software-controlled optical instrument allows for non-invasive detection and assessment of AD by measuring the hallmark of AD, amyloid beta, in the supranuclear region of the lens of the eye. The ligand is administered to the eye as an ophthalmic ointment and a proprietary Fluorescent Ligand Scanning instrument, provides an objective and quantitative measurement of amyloid beta in the patient's lens. Significantly faster and an order of magnitude less expensive than brain imaging, the test and diagnosis can be quickly completed in any physician's office, including general practitioners.

Cognoptix has a strong and com-prehensive patent portfolio covering diagnosis of amyloid beta-based diseases via ophthalmic imaging. The patent portfolio includes issued method and device patents, as well as pending composition of matter patents. In addition to UC San Diego, exclusive licenses have been acquired from Massachusetts General Hospital and Brigham & Women's Hospital Boston.

There are more than 100 new AD drugs that are currently in various stages of research and development. The ability of the Cognoptix drug/device combination to identify and qualify patients for clinical study inclusion, as well as accurately and inexpensively track patient disease progression, may provide pharmaceutical companies with a significant competitive advantage in securing new AD drug approvals. It may also help identify and document differentiating pharmaceutical product performance attributes in Phase IV studies. The technology is currently in clinical trials.

Laura Attwood
Editor, Diagnostics Focus

Click here for the complete issue.

NEWS CRUNCH  
news Gather China & World Pharmaceutical Entrepreneurs, Create a New Chapter of Chinese Pharma Industry
news Mundipharma's New Betadine® Facility to Meet Regional Healthcare Challenges
news STRATASYS launches World's First Full-ColoUr Multi-material 3D PRINTER - THE J750 - In Singapore
PR NEWSWIRE  
Asia Pacific Biotech News
EDITORS' CHOICE  

Healthcare Technology Outlook 2020 - Technology uptake
COLUMNS  
APBN Editorial Calendar 2016
January:
Guest Editorial - Biotechnology In Korea
February:
Guest Editorial - Biomedical Research Governance
March:
Guest Editorial - Life-Saving Opportunities: A Guide to Regenerative Medicine
April:
Leading-Edge ONCOLOGY
May:
Healthcare Systems & Policies in Asia
June:
Medical Devices & Healthcare Technology
July:
Water Technology and Management
August:
Novel Technologies for Antibody Drug Discovery in Japan
September:
Infectious Diseases
October:
Medical Tourism
November:
Biomedical Imaging Technology
December:
Food Technology
Editorial calendar is subjected to changes.
– Editor: Carmen, Jia Wen Loh
MAGAZINE TAGS
About Us
Events
Available issues
Editorial Board
Letters to Editor
Instructions to Authors
Advertise with Us
CONTACT
World Scientific Publishing Co. Pte. Ltd.
5 Toh Tuck Link, Singapore 596224
Tel: 65-6466-5775
Fax: 65-6467-7667
» For Editorial Enquiries:
   biotech_edit@wspc.com or Ms Carmen
» For Subscriptions, Advertisements &
   Media Partnerships Enquiries:
   biotech_ad@wspc.com or Mr Edward
Copyright© 2016 World Scientific Publishing Co Pte Ltd  •  Privacy Policy